These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15171226)

  • 1. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Mercouris BR; Pehlivanidis A; Bouloukos VI; Elisaf M;
    Curr Med Res Opin; 2004 May; 20(5):627-37. PubMed ID: 15171226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Elisaf M; Papageorgiou AA; Symeonidis AN; Pehlivanidis AN; Bouloukos VI; Milionis HJ; Mikhailidis DP;
    Am J Kidney Dis; 2004 Apr; 43(4):589-99. PubMed ID: 15042535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
    Athyros VG; Kakafika AI; Papageorgiou AA; Paraskevas KI; Tziomalos K; Anagnostis P; Pagourelias E; Koumaras C; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2008 Jun; 24(6):1593-9. PubMed ID: 18430270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Pehlivanidis AN; Bouloukos VI; Elisaf M
    J Clin Pathol; 2004 Jul; 57(7):728-34. PubMed ID: 15220366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(8):499-502. PubMed ID: 12564661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Mikhailidis DP; Wierzbicki AS
    Curr Med Res Opin; 2002; 18(4):215-9. PubMed ID: 12201622
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
    Athyros VG; Kakafika AI; Papageorgiou AA; Tziomalos K; Skaperdas A; Pagourelias E; Pirpasopoulou A; Karagiannis A; Mikhailidis DP;
    Lipids; 2007 Nov; 42(11):999-1009. PubMed ID: 17713803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus.
    Athyros VG; Papageorgiou AA; Symeonidis AN; Didangelos TP; Pehlivanidis AN; Bouloukos VI; Mikhailidis DP;
    Angiology; 2003; 54(6):679-90. PubMed ID: 14666956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of blood lipids in colorectal cancer patients with coronary heart disease and value of lipid-lowering therapy with statins].
    Liang ZT; Wang XP; Zeng QT; Liao YH; Gao CY; Li MW
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):863-5. PubMed ID: 18504222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.
    Qi Y; Liu J; Ma C; Wang W; Liu X; Wang M; Lv Q; Sun J; Liu J; Li Y; Zhao D
    J Lipid Res; 2013 Nov; 54(11):3189-97. PubMed ID: 23964121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.